These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 26447531)

  • 21. Numerical simulation of emitted particle characteristics and airway deposition distribution of Symbicort(®) Turbuhaler(®) dry powder fixed combination aerosol drug.
    Farkas Á; Jókay Á; Balásházy I; Füri P; Müller V; Tomisa G; Horváth A
    Eur J Pharm Sci; 2016 Oct; 93():371-9. PubMed ID: 27552906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Acoustic-Based Method to Detect and Quantify the Effect of Exhalation into a Dry Powder Inhaler.
    Holmes MS; Seheult JN; O'Connell P; D'Arcy S; Ehrhardt C; Healy AM; Costello RW; Reilly RB
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):247-53. PubMed ID: 25393346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Numerical simulations of particle behaviour in a realistic human airway model with varying inhalation patterns.
    Kadota K; Inoue N; Matsunaga Y; Takemiya T; Kubo K; Imano H; Uchiyama H; Tozuka Y
    J Pharm Pharmacol; 2020 Jan; 72(1):17-28. PubMed ID: 31713883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tuning aerosol performance using the multibreath Orbital® dry powder inhaler device: controlling delivery parameters and aerosol performance via modification of puck orifice geometry.
    Zhu B; Young PM; Ong HX; Crapper J; Flodin C; Qiao EL; Phillips G; Traini D
    J Pharm Sci; 2015 Jul; 104(7):2169-76. PubMed ID: 25931324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and predictors of suboptimal peak inspiratory flow rate in COPD patients.
    Harb HS; Laz NI; Rabea H; Abdelrahim MEA
    Eur J Pharm Sci; 2020 Apr; 147():105298. PubMed ID: 32151707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Flow Rate on In Vitro Aerodynamic Performance of NEXThaler(®) in Comparison with Diskus(®) and Turbohaler(®) Dry Powder Inhalers.
    Buttini F; Brambilla G; Copelli D; Sisti V; Balducci AG; Bettini R; Pasquali I
    J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):167-78. PubMed ID: 26355743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhalation Profiles Through a Dry Powder Inhaler: Relation Between Inhalation Technique and Spirometric Measures.
    Dorosz A; Urbankowski T; Zieliński K; Michnikowski M; Krenke R; Moskal A
    J Aerosol Med Pulm Drug Deliv; 2021 Dec; 34(6):346-357. PubMed ID: 33877899
    [No Abstract]   [Full Text] [Related]  

  • 28. Dry powder inhaler aerosol deposition in a model of tracheobronchial airways: Validating CFD predictions with in vitro data.
    Ahookhosh K; Saidi M; Aminfar H; Mohammadpourfard M; Hamishehkar H; Yaqoubi S
    Int J Pharm; 2020 Sep; 587():119599. PubMed ID: 32663586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Genuair® inhaler: a novel, multidose dry powder inhaler.
    Chrystyn H; Niederlaender C
    Int J Clin Pract; 2012 Mar; 66(3):309-17. PubMed ID: 22340451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advancement of a Positive-Pressure Dry Powder Inhaler for Children: Use of a Vertical Aerosolization Chamber and Three-Dimensional Rod Array Interface.
    Farkas D; Bonasera S; Bass K; Hindle M; Longest PW
    Pharm Res; 2020 Aug; 37(9):177. PubMed ID: 32862295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of Dry Powder Inhaler Patient Interfaces for Improved Aerosol Delivery to Children.
    Bass K; Longest W
    AAPS PharmSciTech; 2020 May; 21(5):157. PubMed ID: 32451773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The inhalation characteristics of patients when they use different dry powder inhalers.
    Azouz W; Chetcuti P; Hosker HS; Saralaya D; Stephenson J; Chrystyn H
    J Aerosol Med Pulm Drug Deliv; 2015 Feb; 28(1):35-42. PubMed ID: 24815999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study.
    Azouz W; Chetcuti P; Hosker H; Saralaya D; Chrystyn H
    BMC Pulm Med; 2015 May; 15():47. PubMed ID: 25927483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Confusing World of Dry Powder Inhalers: It Is All About Inspiratory Pressures, Not Inspiratory Flow Rates.
    Clark AR; Weers JG; Dhand R
    J Aerosol Med Pulm Drug Deliv; 2020 Feb; 33(1):1-11. PubMed ID: 31613682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Computer modeling of airway deposition distribution of Foster(®) NEXThaler(®) and Seretide(®) Diskus(®) dry powder combination drugs.
    Jókay Á; Farkas Á; Füri P; Horváth A; Tomisa G; Balásházy I
    Eur J Pharm Sci; 2016 Jun; 88():210-8. PubMed ID: 26976481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ease-of-use preference for the ELLIPTA® dry powder inhaler over a commonly used single-dose capsule dry powder inhaler by inhalation device-naïve Japanese volunteers aged 40 years or older.
    Komase Y; Asako A; Kobayashi A; Sharma R
    Int J Chron Obstruct Pulmon Dis; 2014; 9():1365-75. PubMed ID: 25525354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Near Elimination of In Vitro Predicted Extrathoracic Aerosol Deposition in Children Using a Spray-Dried Antibiotic Formulation and Pediatric Air-Jet DPI.
    Farkas D; Thomas ML; Hassan A; Bonasera S; Hindle M; Longest W
    Pharm Res; 2023 May; 40(5):1193-1207. PubMed ID: 35761163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?
    Hochhaus G; Chen MJ; Kurumaddali A; Schilling U; Jiao Y; Drescher SK; Amini E; Berger SM; Kandala B; Tabulov C; Shao J; Seay B; Abu-Hasan MN; Baumstein SM; Winner L; Shur J; Price R; Hindle M; Wei X; Carrasco C; Sandell D; Oguntimein O; Kinjo M; Delvadia R; Saluja B; Lee SL; Conti DS; Bulitta JB
    AAPS J; 2021 Mar; 23(3):48. PubMed ID: 33768368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prerequisites for a dry powder inhaler for children with cystic fibrosis.
    Lexmond AJ; Hagedoorn P; Frijlink HW; Rottier BL; de Boer AH
    PLoS One; 2017; 12(8):e0183130. PubMed ID: 28800360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.